Literature DB >> 33126150

Clinical and pathologic predictors of lymph node metastasis in papillary thyroid microcarcinomas.

Ling Zhao1, Xiaoya Sun2, Yukun Luo3, Fulin Wang4, Zhaohui Lyu5.   

Abstract

Papillary thyroid microcarcinoma (PTMC) has the highest incidence among all thyroid carcinomas. Although surgery is the primary treatment for PTMC, it inevitably leads to trauma and some complications. To formulate an optimal treatment strategy, we aim to clarify the risk factors for lymph node metastasis (LNM) in PTMC patients. This study retrospectively analyzed patients who underwent thyroidectomy during 1995-2015, and grouped them according to lymph node metastasis. Age, gender, tumor size, thyroid functions, Hashimoto's thyroiditis, multifocal tumor, extrathyroidal extensions, capsular invasion were analyzed. Of the 2434 PTMC subjects, proportion of patients with no LNM (NLNM), LNM, central LNM (CLNM), lateral LNM (LLNM), CLNM + LLNM were 82.9%, 17.1%, 7.0%, 7.6% and 2.5%. Patients with NLNM were older and had a lower proportion of males compared to patients with CLNM, LLNM and CLNM + LLNM (p < 0.05). The NLNM group also had a smaller size of ultrasound tumor, lower proportion of multifocal tumor and extrathyroidal extension compared to CLNM, LLNM and CLNM + LLNM groups (p < 0.05). On univariate analyses, male gender, age <45 years, tumor size of pathology (˃0.75 cm), multifocality, and extrathyroidal extension were significantly associated with LNM. Multivariate analyses revealed that male gender, age <45 years, multifocality were risk factors for LNM. In conclusion, PTMC patients with male gender, age <45 years and multifocality should be evaluated carefully for possible LNM.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Central lymph node metastasis; Lateral lymph node metastases; Papillary thyroid microcarcinomas; Predictors

Year:  2020        PMID: 33126150     DOI: 10.1016/j.anndiagpath.2020.151647

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  6 in total

1.  Nomograms Based on Serum N-glycome for Diagnosis of Papillary Thyroid Microcarcinoma and Prediction of Lymph Node Metastasis.

Authors:  Zejian Zhang; Zhen Cao; Rui Liu; Zepeng Li; Jianqiang Wu; Xiaoli Liu; Mengwei Wu; Xiequn Xu; Ziwen Liu
Journal:  Curr Oncol       Date:  2022-08-23       Impact factor: 3.109

2.  Hepatopulmonary metastases from papillary thyroid microcarcinoma: A case report.

Authors:  Chuan-Yu Yang; Xuan-Wu Chen; Dong Tang; Wen-Jun Yang; Xiao-Xiao Mi; Jun-Ping Shi; Wei-Dong Du
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

3.  Construction and validation of a nomogram for predicting cervical lymph node metastasis in classic papillary thyroid carcinoma.

Authors:  Y Feng; Y Min; H Chen; K Xiang; X Wang; G Yin
Journal:  J Endocrinol Invest       Date:  2021-02-14       Impact factor: 4.256

4.  The high degree of similarity in histopathological and clinical characteristics between radiogenic and sporadic papillary thyroid microcarcinomas in young patients.

Authors:  Tetiana Bogdanova; Serhii Chernyshov; Liudmyla Zurnadzhy; Tatiana I Rogounovitch; Norisato Mitsutake; Mykola Tronko; Masahiro Ito; Michael Bolgov; Sergii Masiuk; Shunichi Yamashita; Vladimir A Saenko
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

5.  Ultrasound-based radiomics nomogram combined with clinical features for the prediction of central lymph node metastasis in papillary thyroid carcinoma patients with Hashimoto's thyroiditis.

Authors:  Peile Jin; Jifan Chen; Yiping Dong; Chengyue Zhang; Yajun Chen; Cong Zhang; Fuqiang Qiu; Chao Zhang; Pintong Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

Review 6.  Preoperatively Predicting the Central Lymph Node Metastasis for Papillary Thyroid Cancer Patients With Hashimoto's Thyroiditis.

Authors:  Yu Min; Yizhou Huang; Minjie Wei; Xiaoyuan Wei; Hang Chen; Xing Wang; Jialin Chen; Ke Xiang; Yang Feng; Guobing Yin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-22       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.